Interferon-alpha for follicular lymphoma (Q24247519)

2

0 references

Renato Cannizzaro

3

0 references

Vincenzo Canzonieri

4

0 references

Luigino Dal Maso

5

0 references

Vincenzo Di Lauro

6

0 references

Renzo Lazzarini

7

0 references

Isabella Milan

8

0 references

Maurizio Rupolo

9

0 references

Simona Scalone

10

0 references

Simon Spazzapan

11

0 references

Giuseppe Toffoli

12

0 references

Ivana Truccolo

13

0 references

Antonino Carbone

Cochrane Database of Systematic Reviews

14

0 references

publication date

26 January 2004

0 references

published in

0 references

cites work

New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004629

Role of interferon alfa-2b in the induction and maintenance treatment of low-grade non-Hodgkin's lymphoma: results from a prospective, multicenter trial with double randomization

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004629

A systematic overview of chemotherapy effects in indolent non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004629

Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004629

Systematic overview of cost-utility assessments in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004629

Cytokine therapy for hematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004629

Efficacy, safety, and cost of new anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004629

Maintenance of remission with human recombinant interferon alfa-2a in patients with stages III and IV low-grade malignant non-Hodgkin's lymphoma. European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004629

The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting--Airlie House, Virginia, November, 1997.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004629

Somatic mutations of the translocated bcl-2 gene are associated with morphologic transformation of follicular lymphoma to diffuse large-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004629

Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004629

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004629

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004629

Understanding quality-adjusted life years and their application to pharmacoeconomic research

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004629

A randomized controlled trial to evaluate the role of interferon as initial and maintenance therapy in patients with follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004629

Interferon alfa combined with cytotoxic chemotherapy for patients with non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004629

Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004629

Cost-Effectiveness of interferon alfa-2b added to chemotherapy for high-tumor-burden follicular non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004629

Meta-analysis to assess the efficacy of interferon-alpha in patients with follicular non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004629

inferred from DOI database lookup

7 January 2021

based on heuristic

Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004629